Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493049 | 0.84 | KMT2A (0.31) | KMT2ARECQL | |
| SCHEMBL28776625 | 0.80 | KMT2A (0.33) | HTTKMT2ARECQLSMN1; SMN2 | |
| SCHEMBL27500107 | 0.75 | KDM4E (0.36) | KDM4EGAAHTTTSHR | |
| SCHEMBL14333736 | 0.75 | KDM4E (0.38) | KDM4EGAAHTTTSHRKMT2A | |
| SCHEMBL6427486 | 0.74 | KDM4E (0.33) | KDM4EGAAHTTTSHR | |
| SCHEMBL8977541 | 0.73 | GAA (0.35) | KDM4EGAAHTTTSHRKMT2A | |
| SCHEMBL2104237 | 0.72 | KDM4E (0.31) | KDM4EGAATSHR | |
| SCHEMBL13261284 | 0.72 | HTT (0.41) | KDM4EGAAHTTTSHRKMT2A | |
| SCHEMBL2053373 | 0.72 | KDM4E (0.45) | KDM4EGAAHTTTSHRKMT2A | |
| SCHEMBL4361662 | 0.71 | KDM4E (0.33) | KDM4EGAAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4506340-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Obshestvo s Ogranichennoj Otvetstvennostju "Vikzdorove Zhivotnyh" (RU) | 2025-02-12 | — | — | EP | disclosed |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | OBSHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU "VIK-ZDOROVE ZHIVOTNYKH" (RU) | 2025-01-23 | — | — | US | disclosed |
| US-11945836-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117295718-A | Method for preparing medetomidine and derivative thereof | 维科-兹多洛夫希沃特尼赫有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023182903-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Общество с ограниченной ответственностью "ВИК-здоровье животных" | 2023-09-28 | — | — | WO | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6080871-A | ANTIHISTAMINES | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-06-27 | — | — | US | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | disclosed |
| US-5543526-A | 1-amino-4-(1H-imidazole)- aminobutaneboronic acid derivatives, their preparation and use as synthetic intermediates | SYNTHELABO (FR) | 1996-08-06 | — | — | US | disclosed |
| EP-0677525-A1 | Aminoboronic acid derivatives, their preparation as intermediates in syntheses | SYNTHELABO (FR) | 1995-10-18 | — | — | EP | disclosed |
| EP-0677531-A1 | Derivates of boronic peptides, preparation and use thereof in therapy | SYNTHELABO (FR) | 1995-10-18 | — | — | EP | disclosed |
| US-5359051-A | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945836-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | KDM4E 1501/4885GAA 3369/4885HTT 1548/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | KDM4E 1501/4885GAA 3369/4885HTT 1548/4885 |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | KDM4E 1501/4885GAA 3369/4885HTT 1548/4885 |
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | ADRB2, OPRM1, ADRA2C | KDM4E 1707/4885GAA 4050/4885HTT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.